

CLAIMS

We claim:

1. A substantially pure peptide having the amino acid sequence CKQAGESCDIFSQNCCVG-TCAFICIE-NH₂ (SEQ ID NO 1).
- 5 2. A substantially pure peptide of claim 1, wherein the peptide is used as a sodium channel modulator.
3. A process of preparing substantially pure peptide of claim 1, comprising of:
 - (i) isolation of the peptide, and
 - (ii) purifying the peptide by chromatographic methods,
- 10 4. A process of preparing substantially pure peptide of claim 3, wherein the peptide in step (i) is isolated from venoms of a molluscivorous snail.
5. A process of preparing substantially pure peptide of claim 4, wherein the molluscivorous snail is *Conus amadis*.
6. A process of preparing substantially pure peptide of claim 3, wherein the purification
15 step (ii) is carried out by HPLC (High Performance Liquid Chromatography).
7. A substantially pure peptide of claim 1, wherein the peptide is used for treatment neurophysiological and neurological disorders.
8. A substantially pure peptide of claim 7, wherein the peptide is used for treatment neurophysiological and neurological disorders in schizophrenia, epilepsy, bipolar
20 disorder or in syndromes that affect the nervous system.
9. A pharmaceutical composition comprising a peptide having the amino acid sequence CKQAGESCDIFSQNCCVG-TCAFICIE-NH₂ (SEQ ID NO 1) with or without pharmaceutically acceptable carriers.